Coherus BioSciences Inc. (CHRS)
Coherus BioSciences Statistics
Share Statistics
Coherus BioSciences has 115.9M shares outstanding. The number of shares has increased by 1.02% in one year.
| Shares Outstanding | 115.9M |
| Shares Change (YoY) | 1.02% |
| Shares Change (QoQ) | 0.59% |
| Owned by Institutions (%) | 56.65% |
| Shares Floating | 111.29M |
| Failed to Deliver (FTD) Shares | 1.94K |
| FTD / Avg. Volume | 0.1% |
Short Selling Information
The latest short interest is 32.49M, so 28.03% of the outstanding shares have been sold short.
| Short Interest | 32.49M |
| Short % of Shares Out | 28.03% |
| Short % of Float | 32.7% |
| Short Ratio (days to cover) | 16.16 |
Valuation Ratios
The PE ratio is 5.55 and the forward PE ratio is -1. Coherus BioSciences's PEG ratio is -0.05.
| PE Ratio | 5.55 |
| Forward PE | -1 |
| PS Ratio | 0.59 |
| Forward PS | 0.5 |
| PB Ratio | -1.2 |
| P/FCF Ratio | -7.73 |
| PEG Ratio | -0.05 |
Enterprise Valuation
Currently the Enterprise Value (EV) is not available for Coherus BioSciences.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 1.21, with a Debt / Equity ratio of -1.75.
| Current Ratio | 1.21 |
| Quick Ratio | 0.96 |
| Debt / Equity | -1.75 |
| Debt / EBITDA | 3.8 |
| Debt / FCF | -11.33 |
| Interest Coverage | -4.11 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | $1.17M |
| Profits Per Employee | $125.03K |
| Employee Count | 228 |
| Asset Turnover | 0.6 |
| Inventory Turnover | 1.68 |
Taxes
| Income Tax | 0 |
| Effective Tax Rate | 0% |
Stock Price Statistics
The stock price has increased by -50.49% in the last 52 weeks. The beta is 1.01, so Coherus BioSciences's price volatility has been higher than the market average.
| Beta | 1.01 |
| 52-Week Price Change | -50.49% |
| 50-Day Moving Average | 0.98 |
| 200-Day Moving Average | 1.18 |
| Relative Strength Index (RSI) | 53.99 |
| Average Volume (20 Days) | 1.95M |
Income Statement
In the last 12 months, Coherus BioSciences had revenue of 266.96M and earned 28.51M in profits. Earnings per share was 0.25.
| Revenue | 266.96M |
| Gross Profit | 149.41M |
| Operating Income | -111.67M |
| Net Income | 28.51M |
| EBITDA | 60.94M |
| EBIT | 55.66M |
| Earnings Per Share (EPS) | 0.25 |
Balance Sheet
The company has 125.99M in cash and 231.51M in debt, giving a net cash position of -105.53M.
| Cash & Cash Equivalents | 125.99M |
| Total Debt | 231.51M |
| Net Cash | -105.53M |
| Retained Earnings | -1.55B |
| Total Assets | 448.53M |
| Working Capital | 68.2M |
Cash Flow
In the last 12 months, operating cash flow was -20.44M and capital expenditures 0, giving a free cash flow of -20.44M.
| Operating Cash Flow | -20.44M |
| Capital Expenditures | 0 |
| Free Cash Flow | -20.44M |
| FCF Per Share | -0.18 |
Margins
Gross margin is 55.97%, with operating and profit margins of -41.83% and 10.68%.
| Gross Margin | 55.97% |
| Operating Margin | -41.83% |
| Pretax Margin | 10.68% |
| Profit Margin | 10.68% |
| EBITDA Margin | 22.83% |
| EBIT Margin | -41.83% |
| FCF Margin | -7.66% |
Dividends & Yields
CHRS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | n/a |
| FCF Yield | n/a |
Analyst Forecast
The average price target for CHRS is $7, which is 593.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $7 |
| Price Target Difference | 593.1% |
| Analyst Consensus | Buy |
| Analyst Count | 4 |
Scores
| Altman Z-Score | -4.61 |
| Piotroski F-Score | 4 |